Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies

Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia and higher-risk myelodysplastic syndrome. Of increasing interest are alpha particle-emitting radionuclides such as astatine-211 ((211)At) as they deliver large amounts of radiation over just a few cell diameters, en...

Descripción completa

Detalles Bibliográficos
Autores principales: Laszlo, George S., Orozco, Johnnie J., Kehret, Allie R., Lunn, Margaret C., Huo, Jenny, Hamlin, Donald K., Wilbur, D. Scott, Dexter, Shannon L., Comstock, Melissa L., O’Steen, Shyril, Sandmaier, Brenda M., Green, Damian J., Walter, Roland B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177726/
https://www.ncbi.nlm.nih.gov/pubmed/35474099
http://dx.doi.org/10.1038/s41375-022-01580-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177726/
https://www.ncbi.nlm.nih.gov/pubmed/35474099
http://dx.doi.org/10.1038/s41375-022-01580-7

Ejemplares similares